Tony Sedgwick, former chief executive of Novacta Biosystems Ltd, has been promoted from the position of chief business officer to that of CEO at Silence Therapeutics Plc, a developer of RNA interference (RNAi) therapeutics. He replaces Thomas Christély who has resigned as a director of the company for personal reasons. In addition to heading up Novacta, Dr Sedgwick was formerly chief executive of Daniolabs Ltd and Cambridge Biotechnology Ltd, both of which were sold on to other companies.
Copyright 2012 Evernow Publishing Ltd